Lexicon Pharmaceuticals, Inc.
LXRX
$0.5339
$0.0020.38%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 3,682.62% | 980.25% | 419.56% | 4,608.33% | 2,407.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3,682.62% | 980.25% | 419.56% | 4,608.33% | 2,407.14% |
| Cost of Revenue | 74.84% | 47.17% | 22.41% | 19.77% | 6.12% |
| Gross Profit | 104.39% | -38.49% | -13.56% | -10.59% | -1.30% |
| SG&A Expenses | -32.43% | 22.85% | 30.61% | 67.50% | 90.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.16% | 31.43% | 27.93% | 49.08% | 51.78% |
| Operating Income | 54.88% | -28.33% | -25.12% | -45.57% | -49.60% |
| Income Before Tax | 32.14% | -28.28% | -18.98% | -51.55% | -63.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 32.14% | -28.28% | -18.98% | -51.55% | -63.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 32.14% | -28.28% | -18.98% | -51.55% | -63.17% |
| EBIT | 54.88% | -28.33% | -25.12% | -45.57% | -49.60% |
| EBITDA | 55.01% | -28.47% | -25.22% | -45.63% | -49.63% |
| EPS Basic | 54.01% | 13.09% | 21.61% | -16.69% | -25.68% |
| Normalized Basic EPS | 69.91% | 13.03% | 21.61% | -16.76% | -22.08% |
| EPS Diluted | 54.01% | 13.09% | 21.61% | -16.69% | -25.68% |
| Normalized Diluted EPS | 69.91% | 13.03% | 21.61% | -16.76% | -22.08% |
| Average Basic Shares Outstanding | 47.59% | 47.59% | 51.79% | 29.83% | 29.78% |
| Average Diluted Shares Outstanding | 47.59% | 47.59% | 51.79% | 29.83% | 29.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |